Kruti Joshi, MPH, MD

Is Increased Severity of Major Depressive Disorder Associated With Incremental Economic Burden in Privately Insured US Patients With Treatment Resistant Depression?

Background: Among patients with major depressive disorder (MDD), those with treatment-resistant depression (TRD) have a higher economic burden. However, healthcare resource utilization (H...

Laura Morrison , MPH;

Patrick Lefebvre , MA;

John J. Sheehan , PhD, MBA, RPh;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

Holly Szukis , MPH;

Maryia Zhdanava , MA;

03/01/2019

Characteristics of Commercially Insured Patients Initiated on Esketamine Nasal Spray in a Real-World Setting

BACKGROUND: Esketamine nasal spray was approved for adults with treatment-resistant depression on 03/05/2019. Real-world data on patients initiated on esketamine is limited. METHODS: Adu...

Laura Morrison , MPH;

Swapna Karkare , MS;

Abigail Nash , MD, PhD;

Maryia Zhdanava , MA;

Aditi Shah , MA;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

10/08/2020

Treatment Discontinuation of Long-Acting Injectables or Oral Atypical Antipsychotics Among Medicaid Recipients With Schizophrenia

OBJECTIVE: Compare treatment discontinuation of atypical long-acting injectables (LAIs) and oral atypical antipsychotics (OAA) in patients with schizophrenia.

Xue Song , PhD;

Antoine C. El Khoury , PhD;

Matthew Brouillette , MPH;

Kruti Joshi , MPH, MD;

David Smith , PhD, MD, MBBS, DPM;

03/01/2019

How Well Do Real-World Clinical And Demographic Characteristics Predict Patient Health Questionnaire-9 Scores Among Patients With Treatment-Resistant Depression?

Background: Many real-world databases do not capture the Patient Health Questionnaire-9 (PHQ-9), a self-reported questionnaire used to measure depression severity. We created a model to p...

Xing Liu , MA;

Eros Papademetriou , MA;

Kruti Joshi , MPH, MD;

Ella Daly , MB, BCh, BAO;

Ravi Potluri ;

David Rotter ;

Harsh Kuvadia ;

John J. Sheehan , PhD, MBA, RPh;

Anandaroop Dasgupta , PhD, MS;

11/22/2019

Original Contribution

A Comparison of the Use of Traditional Hand Injection Versus Automated Contrast Injectors During Cardiac Catheterization

11/29/2012

Jeffrey A. Breall , MD, PhD;

Kruti Joshi , MPH, MD;

Robert W. Godley II, MD;

Abstract: Objective. To compare the incidence of contrast-induced nephropathy (CIN) and vascular complications in patients undergoing cardiac catheterization using traditional manual contrast injection techniques with those in which an...

Abstract: Objective. To compare...

11/29/2012

Journal of Invasive Cardiology

Risk of Subsequent Relapses and Corresponding Healthcare Costs Among Recently-Relapsed Medicaid Patients With Schizophrenia

BACKGROUND: Schizophrenia relapses can cause a significant increase in healthcare resource utilization and costs. However, the risk of relapse may be different between patients initiated ...

Edward S. Kim , MD, FACP, MBA;

Patrick Lefebvre , MA;

Dee Lin , PharmD, MS;

Kruti Joshi , MPH, MD;

Bruno Emond , MA;

Charmi Patel , BS , RN, BSN, MPH;

Laura Morrison , MPH;

Maria-Helene Lafeuille , MA;

11/22/2019

Treatment Patterns among Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior Initiated on Esketamine or Traditional Therapies in the United States

Abstract: BACKGROUND: Treatment patterns among adults with major depressive disorder with suicidal ideation or behavior (MDSI) started on esketamine or traditional therapies were describe...

Kruti Joshi , MPH, MD;

01/19/2023

Economic Burden of Treatment Resistant Depression in Privately Insured US Patients With Behavioral Comorbidities

BACKGROUND: Incremental economic burden of treatment resistant depression (TRD) in patients with behavioral comorbidities is largely unknown.

Craig Nelson , MD;

Carmine Rossi , PhD;

Ella Daly , MB, BCh, BAO;

Maryia Zhdanava , MA;

Harsh Kuvadia ;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

11/22/2019

Esketamine Use among Patients with Treatment-resistant Depression Initiating Esketamine and Completing Induction in the United States

Abstract: BACKGROUND: Access to esketamine therapy for treatment-resistant depression (TRD) is available only through certified treatment centers in the US. Therapy starts with induction ...

Kruti Joshi , MPH, MD;

01/19/2023

Prevalence, Incidence and Economic Burden of Schizophrenia Among Medicaid Beneficiaries

Background: Schizophrenia carries a substantial economic burden to healthcare systems and payers. This study aims to update the prevalence, incidence and economic burden of schizophrenia ...

Charmi Patel , BS , RN, BSN, MPH;

Maryia Zhdanava , MA;

Maria-Helene Lafeuille , MA;

Patrick Lefebvre , MA;

Aurélie Côté-Sergent , MSc;

Dominic Pilon , MA;

Dee Lin , PharmD, MS;

Kruti Joshi , MPH, MD;

11/22/2019